- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04907851
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)
A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase II, modular, open label, multicentre study initially opened with ring finger protein 43 (RNF43) loss of function (LoF) mutation-positive pancreatic ductal adenocarcinoma (PDAC) (Module 1) and molecularly unselected biliary tract cancer (BTC) (Module 2) modules. Module 3 will investigate RXC004 in combination with pembrolizumab in BTC. Modules 1 and 2 are monotherapies and Module 3 is the combination therapy.
The primary objective of the study is to assess the preliminary efficacy of RXC004 in each module. This will be evaluated in terms of progression free survival (PFS) at 6 months in Modules 1 and 2, and in terms of Objective response rate (ORR) in Module 3. Following radiological progression, patients will be followed-up for survival.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Wollongong, New South Wales, Australia, 2500
- Wollongong Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3304
- The Alfred Hospital - Alfred Health
-
-
-
-
-
Cambridge, United Kingdom, CB2 0XY
- Cambridge University Hospital NHS Foundation Trust
-
Glasgow, United Kingdom, G12 0YN
- Beatson West of Scotland Cancer Care
-
Leeds, United Kingdom, LS9 7TF
- St James University Hospital
-
London, United Kingdom, NW1 2BU
- University College Hospitals NHS Foundation Trust
-
London, United Kingdom, W12 0HS
- Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
London, United Kingdom, EC1M 6BQ
- Barts Cancer Institute - Haemato-Oncology
-
London, United Kingdom, NW3 2QG
- Royal Free London Foundation NHS Trust
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust - Medical Oncology
-
Oxford, United Kingdom, OX3 7LE
- Oxford Cancer and Haematology Centre Churchill Hospital
-
Sheffield, United Kingdom, S10 2SJ
- Weston Park Hospital
-
Sutton, United Kingdom, SM25PT
- The Royal Marsden Hospital (Surrey)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Core Inclusion Criteria:
- At least one lesion that is measurable by RECIST 1.1 at baseline (within 6 weeks prior to start of study treatment).
- Mandatory paired biopsies; Patients must have at least one lesion suitable for biopsy at screening
- Adequate organ and marrow function
- Female patients of childbearing potential must have a negative pregnancy test prior to start of dosing
- Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use a highly effective method of contraception during the study from the time of treatment initiation, and for at least 5 months after the last dose of study drug.
Module 1 (PDAC) Specific Inclusion Criteria
- Histological documentation of advanced (unresectable)/metastatic (Stage III/IV) PDAC, with documented loss of function tumour mutation in RNF43
- Patients must have received one prior systemic treatment for advanced (unresectable)/metastatic PDAC (Stage III/IV), with clear evidence of radiological disease progression
- Patients must be enrolled and receive first dose of study treatment within 6 weeks of radiologically confirmed progression
- Karnofsky performance status ≥70.
Module 2 and Module 3 (BTC) Specific Inclusion Criteria
- Histological documentation of advanced (unresectable)/metastatic (Stage III/IV) BTC (intrahepatic or extrahepatic cholangiocarcinoma, ampulla of Vater, or gallbladder cancer)
- Patients must have received one prior systemic treatment for advanced (unresectable)/metastatic BTC, with clear evidence of radiological disease progression
- Patients must be enrolled and receive first dose of study treatment within 6 weeks of radiologically confirmed progression
- ECOG status 0 or 1.
Core Exclusion Criteria:
- Prior therapy with a compound of the same mechanism of action as RXC004
- Patients at higher risk of bone fractures
- Any known uncontrolled inter-current illness or persistent clinically significant toxicity related to prior anti-cancer treatment
- Patients who have any history of an active (requiring treatment) other malignancy within 2 years of study entry
- Patients with known or suspected brain metastases
- Use of anti-neoplastic agents
- Patients with a known hypersensitivity to any RXC004 excipients
- Patients with a contra-indication for denosumab treatment
- Patients who are pregnant or breast-feeding
- Known active human immunodeficiency viruses (HIV), hepatitis B (HBV), or hepatitis C (HCV) infections
- Use of any live or live-attenuated vaccines against infectious diseases (e.g., influenza nasal spray, varicella) within 4 weeks (28 days) of initiation of study treatment
- Mean resting corrected QTcF >470 ms, obtained from triplicate ECGs performed at screening.
There are no exclusion criteria specific to Modules 1 and 2.
Module 3 Specific Exclusion Criteria:
- Patients with any contraindication to the use of pembrolizumab as per approved label
- Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor, and was discontinued from that treatment due to a Grade 3 or higher AE
- Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of pembrolizumab in this study
- Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease
- Has an active infection requiring systemic therapy
- Patients with a history of allogeneic tissue/solid organ transplant
- Patients with active infections, including tuberculosis, HIV, HBV, or HCV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Module 1 - RNF43 Mutated Advanced (unresectable)/Metastatic Pancreatic Cancer (Stage III/IV)
Patients (Karnofsky performance status ≥70) will be recruited and dosed with RXC004 (2 mg once daily [QD], orally) within 6 weeks of progression following 1st line SoC treatment.
|
RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
|
Experimental: Module 2 -Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage III/IV)
Patients (Eastern Cooperative Oncology Group [ECOG] performance status 0-1) will be recruited and dosed with RXC004 within 6 weeks of progression, following 1st line SoC treatment.
|
RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
|
Experimental: Module 3-Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage Ill/IV) Combination Therapy
Patients (ECOG performance status 0-1) will be recruited and dosed with RXC004 (1.5 mg QD, orally) in combination with pembrolizumab 400 mg IV infusion every 6 weeks (q6w) within 6 weeks of progression, following 1st line Soc treatment.
|
RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Other Names:
Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monotherapy (Modules 1 and 2): Progression free survival (percent) rate at 6 months using Investigator assessment according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1)
Time Frame: At 6 months
|
To assess the anti-tumour activity of RXC004.
Progression free survival rate at 6 months is defined as the proportion of patients who remain alive and free of progression at 6 months.
|
At 6 months
|
Combination therapy (Module 3): Objective response rate (ORR) using each patient's best overall response (BOR) according to RECIST 1.1
Time Frame: Up to 23 months
|
To assess the anti-tumour activity of RXC004 as combination therapy.
ORR, defined as the proportion of patients with a best overall response of complete response or partial response, based on local investigator assessment, as defined in RECIST 1.1.
|
Up to 23 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the pharmacokinetic (PK) of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Time to Cmax (tmax)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Terminal rate constant (λz)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Terminal half-life (t½)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Total plasma clearance after oral administration (CL/F)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Apparent volume of distribution after oral administration (Vz/F)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At Cycle 0 and Cycle 1 (Each cycle is 21 days in length)
|
Monotherapy (Modules 1 and 2): Objective Response Rate (ORR) using Investigator assessments according to RECIST 1.1
Time Frame: Up to 23 months
|
To further assess the preliminary efficacy of RXC004.
ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), based on local Investigator assessment, as defined in RECIST 1.1.
|
Up to 23 months
|
Monotherapy (Modules 1 and 2) and Combination therapy (Module 3): Disease Control Rate (DCR) using Investigator assessments according to RECIST 1.1
Time Frame: Up to 23 months
|
To further assess the preliminary efficacy of RXC004 as monotherapy and as combination therapy.
DCR is defined as the proportion of patients with a best overall response of either CR, PR or stable disease (SD) for at least 6 weeks.
|
Up to 23 months
|
Monotherapy (Modules 1 and 2) and Combination therapy (Module 3): PFS using Investigator assessments according to RECIST 1.1
Time Frame: Up to 23 months
|
To further assess the preliminary efficacy of RXC004 as monotherapy and as combination therapy.
PFS is defined as the time from first dose of study treatment until the date of disease progression or death (by any cause in the absence of progression), regardless whether the patient withdraws from the assigned study treatment or receives another anticancer prior to progression.
|
Up to 23 months
|
Monotherapy (Modules 1 and 2) and Combination therapy (Module 3): Percentage change in the sum of target lesions using Investigator assessments according to RECIST 1.1
Time Frame: Up to 23 months
|
To further assess the preliminary efficacy of RXC004 as monotherapy and as combination therapy.
Percentage change in tumour size will be derived at each visit by the percentage change from baseline in the sum of diameters of target lesions.
The best percentage change in tumour size will be the patients value representing the largest decrease (or smallest increase) from baseline in tumour size.
|
Up to 23 months
|
Monotherapy (Modules 1 and 2) and Combination therapy (Module 3): Overall survival (OS)
Time Frame: Up to 23 months
|
To further assess the preliminary efficacy of RXC004 as monotherapy and as combination therapy.
OS is defined as the time from first day of study treatment until death due to any cause.
|
Up to 23 months
|
Minimum observed concentration across the dosing interval (Cmin)
Time Frame: At each treatment cycle (Each cycle is 21 days in length), up to 23 months
|
To assess the PK of RXC004 as monotherapy and as combination therapy.
|
At each treatment cycle (Each cycle is 21 days in length), up to 23 months
|
Number of patients with adverse events (AEs)
Time Frame: From time of signature of main study informed consent form throughout the treatment period and until the 30 days after last dose of RXC004 (Up to 23 months)
|
To assess the safety and tolerability profile of RXC004 as monotherapy and as combination therapy.
|
From time of signature of main study informed consent form throughout the treatment period and until the 30 days after last dose of RXC004 (Up to 23 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RXC004/0003
- MK-3475-E86 (Other Identifier: Collaboration requirements)
- KEYNOTE-E86 (Other Identifier: Collaboration requirements)
- 2020-005804-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumours
-
AstraZenecaSyneos HealthCompletedAdvanced Solid TumoursUnited States, Spain, Korea, Republic of, United Kingdom
-
EDDC (Experimental Drug Development Centre), A*STAR...ParexelRecruiting
-
RemeGen Co., Ltd.RecruitingAdvanced Solid TumoursChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced Solid Tumours
-
AstraZenecaActive, not recruiting
-
Exscientia AI LimitedBiotrialTerminatedAdvanced Solid TumoursFrance, Belgium
-
RemeGen Co., Ltd.Recruiting
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited States, Spain
Clinical Trials on RXC004
-
Redx Pharma PlcActive, not recruitingCancer | Solid TumorUnited Kingdom
-
Redx Pharma PlcCompletedColorectal CancerSpain, Korea, Republic of, United Kingdom, United States